# EVOFEM BIOSCIENCES, INC. (EVFM) · Edgar & Edgarette company card

> Evofem Biosciences (EVFM) grew revenue 4.2% in FY2025 to $20 million, operating margin 16.7% against a -3.8% median for pharmaceutical preparations, equity -367% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1618835 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/EVFM) · [JSON](https://www.pops4.com/boards/company/EVFM.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $20M |
| Revenue growth, 1 year | 4.2% |
| Revenue growth per year | 25.1% |
| Operating margin | 16.7% (prior year -39.6%) |
| Net margin | 1.9% |
| Operating cash flow | −$2M |
| Capital spending | $5,000 |
| Free cash flow | −$2M |
| Cash | $578,000 |
| Long-term debt | — |
| Total assets | $20M |
| Total equity | −$74M |
| Equity ÷ assets | -366.7% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -166.55 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Beneish M: -1.85 (below the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; revenue is hard to predict: its 80% range is ±55%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $20.2M (FY2025). Experience: revenue up 4.2% on the year, up 25.1% a year over 4 years; operating margin 16.7%, up from -39.6%. Soundness: equity -366.7% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $11.3M and $38.5M next year (method v4.1: its own 4-year record of growth weighed at 50% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $10.4M to $42.0M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 16.7% against a -3.8% median; growth 4.2% against 13.7%.

Range logged 2026-09-24, receipt 7adbf0377574b103, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 8-K · filed 2026-10-15 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1618835/000149315226047227/0001493152-26-047227-index.htm)
- 8-K · filed 2026-09-23 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1618835/000149315226043919/0001493152-26-043919-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1618835/000149315226038328/0001493152-26-038328-index.htm)
- 8-K · filed 2026-07-20 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1618835/000149315226033910/0001493152-26-033910-index.htm)
- 8-K · filed 2026-07-14 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1618835/000149315226033184/0001493152-26-033184-index.htm)
- 8-K · filed 2026-05-18 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1618835/000149315226024095/0001493152-26-024095-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001618835.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1618835

## Cite

POPS4, Edgar & Edgarette: EVOFEM BIOSCIENCES, INC. (EVFM) company card, from the company's own SEC filings, accessed 2026-11-08, https://www.pops4.com/boards/company/EVFM. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.